Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 453

1.

L’éthique tue-t-elle l’enthousiasme de la recherche ?

Hirschel B.

Rev Med Suisse. 2016 Dec 7;12(542):2137. French. No abstract available.

PMID:
28700169
2.

Ecthyma Gangrenosum: Escherichia coli or Pseudomonas aeruginosa?

Abbas M, Emonet S, Köhler T, Renzi G, van Delden C, Schrenzel J, Hirschel B.

Front Microbiol. 2017 May 30;8:953. doi: 10.3389/fmicb.2017.00953. eCollection 2017.

3.

Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.

Ciaffi L, Cavassini M, Genne D, Delhumeau C, Spycher Elbes R, Hill A, Wandeler G, Fehr J, Stoeckle M, Schmid P, Hirschel B, Montecucco F, Calmy A; Swiss HIV Cohort Study.

Eur J Clin Invest. 2015 Jul;45(7):720-30. doi: 10.1111/eci.12464.

4.

Treatment of Clostridium difficile infection in a French university hospital.

Khanafer N, Blais L, Barbut F, Hirschel B, Vanhems P.

Scand J Gastroenterol. 2015;50(10):1253-60. doi: 10.3109/00365521.2015.1033746. Epub 2015 Apr 15.

PMID:
25877477
5.

Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study.

Carballo D, Delhumeau C, Carballo S, Bähler C, Radovanovic D, Hirschel B, Clerc O, Bernasconi E, Fasel D, Schmid P, Cusini A, Fehr J, Erne P, Keller PF, Ledergerber B, Calmy A; Swiss HIV Cohort Study and AMIS registry.

AIDS Res Ther. 2015 Feb 22;12:4. doi: 10.1186/s12981-015-0045-z. eCollection 2015.

6.

Screening and isolation to control meticillin-resistant Staphylococcus aureus: sense, nonsense, and evidence.

Fätkenheuer G, Hirschel B, Harbarth S.

Lancet. 2015 Mar 21;385(9973):1146-9. doi: 10.1016/S0140-6736(14)60660-7. Epub 2014 Aug 20. No abstract available.

PMID:
25150745
7.

HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.

Bunupuradah T, Bowonwattanuwong C, Jirajariyavej S, Munsakul W, Klinbuayaem V, Sophonphan J, Mahanontharit A, Hirschel B, Ruxrungtham K, Ananworanich J; HIV STAR Study team.

Antivir Ther. 2014;19(6):579-86. doi: 10.3851/IMP2737. Epub 2014 Jan 24.

PMID:
24464590
8.

Micro-structural brain alterations in aviremic HIV+ patients with minor neurocognitive disorders: a multi-contrast study at high field.

Granziera C, Daducci A, Simioni S, Cavassini M, Roche A, Meskaldji D, Kober T, Metral M, Calmy A, Helms G, Hirschel B, Lazeyras F, Meuli R, Krueger G, Du Pasquier RA.

PLoS One. 2013 Sep 10;8(9):e72547. doi: 10.1371/journal.pone.0072547. eCollection 2013.

9.

The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients.

Beerenwinkel N, Montazeri H, Schuhmacher H, Knupfer P, von Wyl V, Furrer H, Battegay M, Hirschel B, Cavassini M, Vernazza P, Bernasconi E, Yerly S, Böni J, Klimkait T, Cellerai C, Günthard HF; Swiss HIV Cohort Study.

PLoS Comput Biol. 2013;9(8):e1003203. doi: 10.1371/journal.pcbi.1003203. Epub 2013 Aug 29.

10.

Capnocytophaga canimorsus prosthetic aortitis in an HIV-positive woman.

Rougemont M, Ratib O, Wintsch J, Schrenzel J, Hirschel B.

J Clin Microbiol. 2013 Aug;51(8):2769-71. doi: 10.1128/JCM.00321-13. Epub 2013 May 22.

11.

A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.

Aouri M, Calmy A, Hirschel B, Telenti A, Buclin T, Cavassini M, Rauch A, Decosterd LA.

J Mass Spectrom. 2013 May;48(5):616-25. doi: 10.1002/jms.3200.

PMID:
23674286
12.

The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study.

Wang Q, Young J, Bernasconi E, Cavassini M, Vernazza P, Hirschel B, Weber R, Furrer H, Stoeckle M, Bucher HC, Fux C; Swiss HIV Cohort Study.

Antivir Ther. 2013;18(3):337-44. doi: 10.3851/IMP2372. Epub 2012 Sep 12.

PMID:
23603864
13.

Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study.

Simioni S, Cavassini M, Annoni JM, Métral M, Iglesias K, Rimbault Abraham A, Jilek S, Calmy A, Müller H, Fayet-Mello A, Giacobini E, Hirschel B, Du Pasquier RA.

Neurology. 2013 Feb 5;80(6):553-60. doi: 10.1212/WNL.0b013e3182815497. Epub 2013 Jan 23.

PMID:
23345635
14.

A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.

Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K; HIV STAR Study Group.

Antivir Ther. 2012;17(7):1351-61. doi: 10.3851/IMP2443. Epub 2012 Jul 2. Erratum in: Antivir Ther. 2012;17(7):1389-90.

PMID:
23075703
15.

Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections.

Ambrosioni J, Junier T, Delhumeau C, Calmy A, Hirschel B, Zdobnov E, Kaiser L, Yerly S; Swiss HIV Cohort Study.

AIDS. 2012 Oct 23;26(16):2079-86. doi: 10.1097/QAD.0b013e32835805b6.

PMID:
23052354
16.

Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.

Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, Günthard HF; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):28-35. doi: 10.1097/QAI.0b013e318274e2b0. Erratum in: J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e170-1.

PMID:
23018371
17.

Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.

Bunupuradah T, Chetchotisakd P, Jirajariyavej S, Valcour V, Bowonwattanuwong C, Munsakul W, Klinbuayaem V, Prasithsirikul W, Sophonphan J, Mahanontharit A, Hirschel B, Bhakeecheep S, Ruxrungtham K, Ananworanich J; HIV STAR Study Group.

J Neurovirol. 2012 Dec;18(6):479-87. doi: 10.1007/s13365-012-0127-9. Epub 2012 Sep 20.

PMID:
22993101
18.

Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.

Elzi L, Erb S, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M; Swiss HIV Cohort Study.

Arch Intern Med. 2012 Sep 24;172(17):1313-21. doi: 10.1001/archinternmed.2012.3216.

PMID:
22892835
19.

Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.

Siegrist CA, van Delden C, Bel M, Combescure C, Delhumeau C, Cavassini M, Clerc O, Meier S, Hadaya K, Soccal PM, Yerly S, Kaiser L, Hirschel B, Calmy A; H1N1 Study Group; Swiss HIV Cohort Study (SHCS).

PLoS One. 2012;7(7):e40428. doi: 10.1371/journal.pone.0040428. Epub 2012 Jul 27.

20.

Infectious diseases publications in leading medical journals--a comparative analysis.

Fätkenheuer G, Roer F, Hirschel B, Cornely OA, Salzberger B.

Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2585-91. Epub 2012 Apr 14.

PMID:
22526868
21.

HLA-Bw4 identifies a population of HIV-infected patients with an increased capacity to control viral replication after structured treatment interruption.

Stern M, Czaja K, Rauch A, Rickenbach M, Günthard HF, Battegay M, Fellay J, Hirschel B, Hess C; Swiss HIV Cohort Study Group.

HIV Med. 2012 Nov;13(10):589-95. doi: 10.1111/j.1468-1293.2012.01019.x. Epub 2012 Apr 15.

22.

Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.

Aouri M, Decosterd LA, Buclin T, Hirschel B, Calmy A, Livio F.

AIDS. 2012 Mar 27;26(6):776-8. doi: 10.1097/QAD.0b013e328351f662. No abstract available.

PMID:
22436541
23.

Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.

Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Kovari H, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, Günthard HF, Wong JK; Swiss HIV Cohort Study.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3035-40. doi: 10.1073/pnas.1111573109. Epub 2012 Feb 6.

24.

Kidney light chain disease in patients with the acquired immunodeficiency syndrome.

Villaverde RV, Darioli V, Hirschel B, McKee TA, Lobrinus JA, Moll S.

Clin Kidney J. 2012 Feb;5(1):59-62. doi: 10.1093/ckj/sfr176.

25.

Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.

Glass TR, Rotger M, Telenti A, Decosterd L, Csajka C, Bucher HC, Günthard HF, Rickenbach M, Nicca D, Hirschel B, Bernasconi E, Wandeler G, Battegay M, Marzolini C; Swiss HIV Cohort Study.

PLoS One. 2012;7(1):e29186. doi: 10.1371/journal.pone.0029186. Epub 2012 Jan 3.

26.

A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA.

Wandeler G, Keiser O, Hirschel B, Günthard HF, Bernasconi E, Battegay M, Clerc O, Vernazza PL, Furrer H; Swiss HIV Cohort Study.

PLoS One. 2011;6(12):e27903. doi: 10.1371/journal.pone.0027903. Epub 2011 Dec 20.

27.

Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study.

Bucher HC, Richter W, Glass TR, Magenta L, Wang Q, Cavassini M, Vernazza P, Hirschel B, Weber R, Furrer H, Battegay M, Bernasconi E.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):135-42. doi: 10.1097/QAI.0b013e31824476e1.

PMID:
22156913
28.

Diagnosing acute HIV infection.

Yerly S, Hirschel B.

Expert Rev Anti Infect Ther. 2012 Jan;10(1):31-41. doi: 10.1586/eri.11.154. Review.

PMID:
22149612
29.

Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.

Wyl Vv, Gianella S, Fischer M, Niederoest B, Kuster H, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF; Swiss HIV Cohort Study-SHCS.

PLoS One. 2011;6(11):e27463. doi: 10.1371/journal.pone.0027463. Epub 2011 Nov 15.

30.

Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients.

Calmy A, Bel M, Nguyen A, Combescure C, Delhumeau C, Meier S, Yerly S, Kaiser L, Hirschel B, Siegrist CA; H1N1 Study Group.

HIV Med. 2012 Apr;13(4):207-18. doi: 10.1111/j.1468-1293.2011.00961.x. Epub 2011 Nov 7.

31.

Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection.

Elzi L, Steffen I, Furrer H, Fehr J, Cavassini M, Hirschel B, Hoffmann M, Bernasconi E, Bassetti S, Battegay M.

BMC Infect Dis. 2011 Nov 15;11:319. doi: 10.1186/1471-2334-11-319.

32.

Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations.

von Wyl V, Yerly S, Böni J, Shah C, Cellerai C, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2012 Jan 1;54(1):131-40. doi: 10.1093/cid/cir728. Epub 2011 Nov 4.

33.

Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.

Bunupuradah T, Ananworanich J, Chetchotisakd P, Kantipong P, Jirajariyavej S, Sirivichayakul S, Munsakul W, Prasithsirikul W, Sungkanuparph S, Bowonwattanuwong C, Klinbuayaem V, Petoumenos K, Hirschel B, Bhakeecheep S, Ruxrungtham K.

Antivir Ther. 2011;16(7):1113-21. doi: 10.3851/IMP1906.

PMID:
22024527
34.

Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.

Scherrer AU, Ledergerber B, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser P, Rauch A, Hirschel B, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Held L, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2011 Dec;53(11):1143-52. doi: 10.1093/cid/cir669. Epub 2011 Oct 13.

35.

Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study.

Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R; Swiss HIV Cohort Study.

Clin Infect Dis. 2011 Dec;53(11):1130-9. doi: 10.1093/cid/cir626. Epub 2011 Oct 13.

36.

High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease.

Schüpbach J, Bisset LR, Regenass S, Bürgisser P, Gorgievski M, Steffen I, Andreutti C, Martinetti G, Shah C, Yerly S, Klimkait T, Gebhardt M, Schöni-Affolter F, Rickenbach M; Swiss HIV Cohort Study, Barth J, Battegay M, Bernascon E, Böni J, Bucher HC, Bürgisser P, Burton-Jeangros C, Calmy A, Cavassini M, Dubs R, Egger M, Elzi L, Fehr J, Fischer M, Flepp M, Francioli P, Furrer H, Fux CA, Gorgievski M, Günthard H, Hasse B, Hirsch HH, Hirschel B, Hösli I, Kahlert C, Kaiser L, Keiser O, Kind C, Klimkait T, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Müller N, Nadal D, Pantaleo G, Rauch A, Regenass S, Rickenbach M, Rudin C, Schmid P, Schultze D, Schöni-Affolter F, Schüpbach J, Speck R, Taffé P, Telenti A, Trkola A, Vernazza P, von Wyl V, Weber R, Yerly S.

BMC Infect Dis. 2011 Sep 26;11:254. doi: 10.1186/1471-2334-11-254.

37.

The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland.

von Wyl V, Kouyos RD, Yerly S, Böni J, Shah C, Bürgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M, Staehelin C, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard HF; Swiss HIV Cohort Study.

J Infect Dis. 2011 Oct 1;204(7):1095-103. doi: 10.1093/infdis/jir491.

38.

Impaired antibody memory to varicella zoster virus in HIV-infected children: low antibody levels and avidity*.

L'Huillier AG, Ferry T, Courvoisier DS, Aebi C, Cheseaux JJ, Kind C, Rudin C, Nadal D, Hirschel B, Sottas C, Siegrist CA, Posfay-Barbe KM; Pediatric Infectious Diseases Group of Switzerland; Group of Switzerland (PIGS); Swiss HIV Cohort Study (SHCS); Swiss Mother & Child HIV Cohort Study (MoCHiV).

HIV Med. 2012 Jan;13(1):54-61. doi: 10.1111/j.1468-1293.2011.00936.x. Epub 2011 Jul 3.

39.

Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.

Gianella S, von Wyl V, Fischer M, Niederoest B, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2011;16(4):535-45. doi: 10.3851/IMP1776.

PMID:
21685541
40.

HIV treatment for prevention.

Ambrosioni J, Calmy A, Hirschel B.

J Int AIDS Soc. 2011 May 25;14:28. doi: 10.1186/1758-2652-14-28. Review.

41.

A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).

Nguyen A, Calmy A, Delhumeau C, Mercier I, Cavassini M, Mello AF, Elzi L, Rauch A, Bernasconi E, Schmid P, Hirschel B.

AIDS. 2011 Jul 31;25(12):1481-7. doi: 10.1097/QAD.0b013e328348dab0.

PMID:
21593661
42.

Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque.

Rotger M, Dalmau J, Rauch A, McLaren P, Bosinger SE, Martinez R, Sandler NG, Roque A, Liebner J, Battegay M, Bernasconi E, Descombes P, Erkizia I, Fellay J, Hirschel B, Miró JM, Palou E, Hoffmann M, Massanella M, Blanco J, Woods M, Günthard HF, de Bakker P, Douek DC, Silvestri G, Martinez-Picado J, Telenti A.

J Clin Invest. 2011 Jun;121(6):2391-400. doi: 10.1172/JCI45235. Epub 2011 May 9.

43.

Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection.

Haas A, Zimmermann K, Graw F, Slack E, Rusert P, Ledergerber B, Bossart W, Weber R, Thurnheer MC, Battegay M, Hirschel B, Vernazza P, Patuto N, Macpherson AJ, Günthard HF, Oxenius A; Swiss HIV Cohort Study.

Gut. 2011 Nov;60(11):1506-19. doi: 10.1136/gut.2010.224774. Epub 2011 Apr 21.

44.

Successful efavirenz dose reduction guided by therapeutic drug monitoring.

Fayet Mello A, Buclin T, Decosterd LA, Delhumeau C, di Iulio J, Fleurent A, Schneider MP, Cavassini M, Telenti A, Hirschel B, Calmy A.

Antivir Ther. 2011;16(2):189-97. doi: 10.3851/IMP1742.

PMID:
21447868
45.

Genital shedding of HIV after scheduled treatment interruption.

Ananworanich J, Kerr SJ, Vernazza P, Mangclaviraj S, Chaithongwongwatthana S, Chotnopparatpattara P, Mahanontharit A, Ubolyam S, Jupimai T, Cooper DA, Ruxrungtham K, Hirschel B; Staccato HIV-NAT Study Group.

Int J STD AIDS. 2011 Feb;22(2):61-6. doi: 10.1258/ijsa.2010.009594.

PMID:
21427425
46.

[HIV and AIDS: what's new in 2010?].

Calmy A, Schiffer V, Hirschel B.

Rev Med Suisse. 2011 Jan 19;7(278):159-63. French.

PMID:
21400951
47.

Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance.

di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J, Martinez R, Pulit S, Furrer H, Günthard HF, Battegay M, Bernasconi E, Schmid P, Hirschel B, Barnes E, Klenerman P, Telenti A, Rauch A; Swiss HIV Cohort Study.

Hepatology. 2011 May;53(5):1446-54. doi: 10.1002/hep.24263.

48.

Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.

Lubomirov R, Colombo S, di Iulio J, Ledergerber B, Martinez R, Cavassini M, Hirschel B, Bernasconi E, Elzi L, Vernazza P, Furrer H, Günthard HF, Telenti A; Swiss HIV Cohort Study.

J Infect Dis. 2011 Jan 15;203(2):246-57. doi: 10.1093/infdis/jiq043. Epub 2010 Dec 9.

49.

Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors.

Scherrer AU, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser P, Garzoni C, Hirschel B, Cavassini M, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Günthard HF; Swiss HIV Cohort Study (SHCS).

J Acquir Immune Defic Syndr. 2011 May 1;57(1):24-31. doi: 10.1097/QAI.0b013e318211925e.

PMID:
21283013
50.

Risk of influenza-like illness in an acute health care setting during community influenza epidemics in 2004-2005, 2005-2006, and 2006-2007: a prospective study.

Vanhems P, Voirin N, Roche S, Escuret V, Regis C, Gorain C, Pires-Cronenberger S, Giard M, Lina B, Najioullah F, Barret B, Pollissard L, David S, Crozet MN, Comte B, Hirschel B, Ecochard R.

Arch Intern Med. 2011 Jan 24;171(2):151-7. doi: 10.1001/archinternmed.2010.500.

PMID:
21263105

Supplemental Content

Loading ...
Support Center